Ipragliflozin L-Proline

Ipragliflozin L-Proline (CAS No.: 951382-34-6) is a synthetic small molecule and glucose transporter biology tool compound classified as a highly potent and selective inhibitor of sodium glucose cotransporter 2, with functional activity centered on blockade of renal SGLT2 mediated glucose reabsorption pathways and minimal activity reported against related SGLT family members including SGLT1 and SGLT3 through SGLT6, supporting its use as a target focused probe for transporter selectivity studies in metabolic research systems. Across reported biochemical and transporter assays, inhibitory potency is consistently observed in the nanomolar range, including low single digit nanomolar to high single digit nanomolar levels in human, rat, and mouse SGLT2 contexts, which makes this compound suitable for cross species pharmacology comparisons, mechanism based pathway interrogation, and structure activity relationship benchmarking in discovery programs focused on glucose handling biology. In biomedical research workflows, it is commonly applied in in vitro transporter assays, engineered cell systems expressing SGLT isoforms, and in vivo rodent models designed to evaluate pharmacodynamic consequences of selective SGLT2 inhibition, while experimental concentrations or dose regimens are generally determined by study specific objectives, assay format, exposure duration, and endpoint sensitivity. As a catalog research reagent, it is most appropriately positioned for use in basic and translational investigations of transporter pharmacology, metabolic signaling networks linked to renal glucose flux, and preclinical screening cascades that require a well characterized selective SGLT2 reference inhibitor.